Paroxysmal nocturnal hemoglobinuria
Drug research and approvals for paroxysmal nocturnal hemoglobinuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 29 studies of paroxysmal nocturnal hemoglobinuria are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, and FDA has 9 approved and 10 open orphan designations naming it.
- Recruiting worldwide: 29
- Trials authorized in Canada: 23
- FDA orphan approvals: 9
- EU medicines: 0
- Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National…NCT07877727 · Not reported · Istituto Giannina Gaslini · starts May 29, 2025
- To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.NCT07760467 · Phase 1 · Zhuhai United Laboratories Co., Ltd. · starts Aug 26, 2026
- Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT07470762 · Phase 1 / Phase 2 · Jiangsu Hansoh Pharmaceutical Co., Ltd. · starts Feb 14, 2026
- A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy ParticipantsNCT07462780 · Phase 1 · Shenzhen Kangzhe Biotechnology Co., Ltd. · starts Mar 5, 2026
- Danicopan PMS in KoreaNCT07457151 · Not reported · AstraZeneca · starts Apr 10, 2026
- A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyNCT07416162 · Not reported · Novartis Pharmaceuticals · starts Jun 15, 2026
- A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT07256301 · Phase 1 · Shanghai Lanyi Therapeutics Co., Ltd. · starts Jan 3, 2024
- REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal HemoglobinuriaNCT07229235 · Not reported · Novartis Pharmaceuticals · starts Jan 13, 2026
- A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B,…NCT07187401 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Feb 11, 2026
| Jul 9, 2025 | A single arm study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria…Cemdisiran (ALN-CC5) / Pozelimab (REGN3918) | Regeneron | Ongoing |
| Jun 30, 2025 | A phase 3 open-label study of danicopan as add-on treatment to ravulizumab or eculizumab in pediatric participants with paroxysmal nocturnal hemoglobinuria who…Danicopan (ALXN2040) | AstraZeneca Pharmaceuticals | Ongoing |
| May 7, 2025 | A randomized, double-blind, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of aln-cfb, an…Aln-cfb (ALN-1725763) | Regeneron | Ongoing |
| Nov 21, 2022 | Long-term extension (LTE) study to characterize the safety and efficacy of danicopan as an add-on therapy to a complement component 5 inhibitor (C5I) in…Danicopan (ALXN2040) | AstraZeneca Pharmaceuticals | Ongoing |
| Oct 6, 2022 | An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of pozelimab and cemdisiran combination therapy in patients with…Pozelimab (REGN3918) / Cemdisiran (ALN-CC5). | Regeneron | Ongoing |
| Mar 16, 2022 | A randomized, open-label, ravulizumab-controlled study to evaluate the efficacy and safety of pozelimab and cemdisiran combination therapy in patients with…Pozelimab (REGN3918) / Cemdisiran (ALN-CC5) / Ravulizumab | Regeneron | Ongoing |
| Sep 16, 2021 | A randomized, double-blind, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of oral BCX9930…BCX9930 | BioCryst Pharmaceuticals | Pending |
| Sep 8, 2021 | A randomized, open-label, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of oral BCX9930 monotherapy for the treatment of…BCX9930 | BioCryst Pharmaceuticals | Pending |
| Jul 28, 2021 | Phase 2 open-label proof of concept study to assess the efficacy, safety, andpharmacokinetics of the oral factor d (FD) inhibitor ALXN2050 (ACH-0145228)in…ALXN2050 | AstraZeneca Pharmaceuticals | Closed |
| Nov 20, 2020 | A phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of crovalimab versus eculizumab in adult and…Crovalimab (RO7112689) / Eculizumab | Roche | Closed |
| Jun 20, 2024 | PiaskyTreatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40… | Genentech Inc. | Approved |
| Mar 29, 2024 | VoydeyaAdd-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal… | Alexion Pharmaceuticals, Inc | Approved |
| Dec 5, 2023 | FabhaltaTreatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) | Novartis Pharmaceuticals Corporation | Approved |
| Jul 22, 2022 | UltomirisTreatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) | Alexion Pharmaceuticals, Inc. | Approved |
| Jun 7, 2021 | UltomirisTreatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) | Alexion Pharmaceuticals, Inc. | Approved |
| May 14, 2021 | EmpaveliTreatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) | Apellis Pharmaceuticals, Inc. | Approved |
| Oct 9, 2020 | UltomirisULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). | Alexion Pharmaceuticals, Inc. | Approved |
| Dec 21, 2018 | UltomirisULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). | Alexion Pharmaceuticals, Inc. | Approved |
| Mar 16, 2007 | SolirisTreatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis | Alexion Pharmaceuticals, Inc. | Approved |
| Dec 11, 2024 | Small molecule inhibitor of complement factor BTreatment of paroxysmal nocturnal hemoglobinuria | Wuhan Createrna Science and Technology Co., Ltd. | Designated |
| Dec 20, 2023 | Recombinant, Humanized, Aglycosylated, Immunoglobulin G1…Treatment of paroxysmal nocturnal hemoglobinuria | NovelMed Therapeutics, Inc. | Designated |
| Oct 5, 2022 | Recombinant, Humanized, aglycosylated, IgG1 Kappa…Treatment of Paroxysmal Nocturnal Hemoglobinuria | NovelMed Therapeutics, Inc. | Designated |
| Jul 28, 2022 | Humanized immunoglobulin G4 monoclonal antibody directed…Treatment of Paroxysmal Nocturnal Hemoglobinuria | Novo Nordisk Inc. | Designated |
| Jul 20, 2022 | Recombinant IgG-fusion protein containing a humanized…Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) | Kira Pharmaceuticals, LLC | Designated |
| Feb 10, 2022 | CemdisiranTreatment of paroxysmal nocturnal hemoglobinuria | Regeneron Pharamecuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA